Effects of buspirone on an animal model of tardive dyskinesia

dc.contributor.authorQueiroz, Claudio MT [UNIFESP]
dc.contributor.authorFrussa-Filho, Roberto [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:30:55Z
dc.date.available2016-01-24T12:30:55Z
dc.date.issued1999-11-01
dc.description.abstract1. the effects of buspirone were studied on an animal model of tardive dyskinesia, i.e., the quantification of orofacial dyskinesia in rats repeatedly treated with reserpine.2. Rats were co-treated with saline [SAL] or buspirone [BUS] (3.0 mg/kg, i.p., twice daily) and vehicle [VEH] or reserpine [RES] (0.1 mg/kg, s.c., once every other day) for 19 days. On the day 20, the animals were observed for quantification of the behavioral parameters of orofacial dyskinesia: tongue protrusion and vacuous chewing movements frequencies and duration of twitching of the facial musculature.3. Rats of the SAL+RES group exhibited a significant increase in the three behavioral parameters of orofacial dyskinesia relative to the rats of the SAL+VEH group. However, animals of the BUS+RES group showed only an increased frequency of vacuous chewing movements when compared to animals of the SAL+VEH group. in addition, the duration of the facial twitching was significantly decreased in the BUS+RES group in relation to rats of the SAL+RES group. There were no significant differences in the orofacial parameters between the BUS+VEH and the SAL+VEH groups.4. Because it was also verified that chronic buspirone treatment was able to increase apomorphine-induced yawning behavior, the possibility is raised that buspirone attenuates reserpine-induced orofacial dyskinesia through the development of dopamine autoreceptor supersensitivity.en
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Dept Pharmacol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Dept Pharmacol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent1405-1418
dc.identifierhttp://dx.doi.org/10.1016/S0278-5846(99)00074-3
dc.identifier.citationProgress in Neuro-psychopharmacology & Biological Psychiatry. Oxford: Pergamon-Elsevier B.V., v. 23, n. 8, p. 1405-1418, 1999.
dc.identifier.doi10.1016/S0278-5846(99)00074-3
dc.identifier.issn0278-5846
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/26170
dc.identifier.wosWOS:000083628500007
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofProgress in Neuro-psychopharmacology & Biological Psychiatry
dc.rightsAcesso restrito
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectbuspironeen
dc.subjectdopamineen
dc.subjectorofacial movementsen
dc.subjectraten
dc.subjectreserpineen
dc.subjectserotoninen
dc.subjecttardive dyskinesiaen
dc.titleEffects of buspirone on an animal model of tardive dyskinesiaen
dc.typeResenha
Arquivos